Hajiasgharzadeh K, Somi MH, Shanehbandi D, Mokhtarzadeh A, Baradaran B. Small interfering RNA-mediated gene suppression as a therapeutic intervention in hepatocellular carcinoma. J Cell Physiol. 2019;234:3263–76. https://doi.org/10.1002/jcp.27015.

Article  CAS  PubMed  Google Scholar 

Chen S, Cao Q, Wen W, Wang H. Targeted therapy for hepatocellular carcinoma: challenges and opportunities. Cancer Lett. 2019;460:1–9. https://doi.org/10.1016/j.canlet.2019.114428.

Article  CAS  PubMed  Google Scholar 

Ferenci P, Fried M, Labrecque D, Bruix J, Sherman M, Omata M, et al. Hepatocellular carcinoma (HCC): a global perspective. J Clin Gastroenterol. 2010;44:239–45. https://doi.org/10.1097/MCG.0b013e3181d46ef2.

Article  PubMed  Google Scholar 

Le Grazie M, Biagini MR, Tarocchi M, Polvani S, Galli A. Chemotherapy for hepatocellular carcinoma: the present and the future. World J Hepatol. 2017;9:907–20. https://doi.org/10.4254/wjh.v9.i21.907.

Article  PubMed  PubMed Central  Google Scholar 

Cagel M, Grotz E, Bernabeu E, Moretton MA, Chiappetta DA. Doxorubicin: nanotechnological overviews from bench to bedside. Drug Discovery Today. 2017;22:270–81. https://doi.org/10.1016/j.drudis.2016.11.005.

Article  CAS  PubMed  Google Scholar 

Radu ER, Semenescu A, Voicu SI. Recent advances in stimuli-responsive doxorubicin delivery systems for liver cancer therapy. Polymers. 2022;14:5249.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mohammadi M, Arabi L, Alibolandi M. Doxorubicin-loaded composite nanogels for cancer treatment. J Control Release. 2020;328:171–91. https://doi.org/10.1016/j.jconrel.2020.08.033.

Article  CAS  PubMed  Google Scholar 

Yue W, Yupeng G, Jun C, Kui J. Apatinib combined with olaparib induces ferroptosis via a p53-dependent manner in ovarian cancer. J Cancer Res Clin Oncol. 2023;149:8681–9. https://doi.org/10.1007/s00432-023-04811-1.

Article  CAS  PubMed  Google Scholar 

Sturm M-J, Henao-Restrepo JA, Becker S, Proquitté H, Beck JF, Sonnemann J. Synergistic anticancer activity of combined ATR and ribonucleotide reductase inhibition in Ewing’s sarcoma cells. J Cancer Res Clin Oncol. 2023;149:8605–17. https://doi.org/10.1007/s00432-023-04804-0.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Özgür A, Tutar Y. Heat shock protein 90 inhibition in cancer drug discovery: from chemistry to futural clinical applications. Anticancer Agents Med Chem. 2016;16:280–90. https://doi.org/10.2174/1871520615666150821093747.

Article  CAS  PubMed  Google Scholar 

Verma S, Goyal S, Jamal S, Singh A, Grover A. Hsp90: friends, clients and natural foes. Biochimie. 2016;127:227–40. https://doi.org/10.1016/j.biochi.2016.05.018.

Article  CAS  PubMed  Google Scholar 

Ren X, Li T, Zhang W, Yang X. Targeting heat-shock protein 90 in cancer: an update on combination therapy. Cells. 2022;11:2556.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Qin L, Huang H, Huang J, Wang G, Huang J, Wu X, et al. Biological characteristics of heat shock protein 90 in human liver cancer cells. Am J Transl Res. 2019;11:2477–83.

CAS  PubMed  PubMed Central  Google Scholar 

Wei W, Liu M, Ning S, Wei J, Zhong J, Li J, et al. Diagnostic value of plasma HSP90α levels for detection of hepatocellular carcinoma. BMC Cancer. 2020;20:6. https://doi.org/10.1186/s12885-019-6489-0.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Özgür A. Investigation of anticancer activities of STA-9090 (ganetespib) as a second generation HSP90 inhibitor in Saos-2 osteosarcoma cells. J Chemother. 2021;33:554–63. https://doi.org/10.1080/1120009X.2021.1908650.

Article  PubMed  Google Scholar 

Ozgur A, Tutar Y. Heat shock protein 90 inhibitors in oncology. Curr Proteomics. 2014;11:2–16.

Article  CAS  Google Scholar 

Bussenius J, Blazey CM, Aay N, Anand NK, Arcalas A, Baik T, et al. Discovery of XL888: a novel tropane-derived small molecule inhibitor of HSP90. Bioorg Med Chem Lett. 2012;22:5396–404. https://doi.org/10.1016/j.bmcl.2012.07.052.

Article  CAS  PubMed  Google Scholar 

Zhang Y, Ware MB, Zaidi MY, Ruggieri AN, Olson BM, Komar H, et al. Heat shock protein-90 inhibition alters activation of pancreatic stellate cells and enhances the efficacy of PD-1 blockade in pancreatic cancer. Mol Cancer Ther. 2021;20:150–60. https://doi.org/10.1158/1535-7163.Mct-19-0911.

Article  CAS  PubMed  Google Scholar 

Vido MJ, Aplin AE. The broad stroke of Hsp90 inhibitors: painting over the RAF inhibitor paradox. J Investig Dermatol. 2015;135:2355–7. https://doi.org/10.1038/jid.2015.239.

Article  CAS  PubMed  Google Scholar 

Tosun NG, Kaplan Ö, Özgür A. Apoptosis induced by Tarantula cubensis crude venom (Theranekron® D6) in cancer cells. Rev Bras. 2021;31:824–31. https://doi.org/10.1007/s43450-021-00221-x.

Article  CAS  Google Scholar 

Kaplan Ö, Gökşen Tosun N, İmamoğlu R, Türkekul İ, Gökçe İ, Özgür A. Biosynthesis and characterization of silver nanoparticles from Tricholoma ustale and Agaricus arvensis extracts and investigation of their antimicrobial, cytotoxic, and apoptotic potentials. J Drug Deliv Sci Technol. 2022;69:103178. https://doi.org/10.1016/j.jddst.2022.103178.

Article  CAS  Google Scholar 

Schicht G, Seidemann L, Haensel R, Seehofer D, Damm G. Critical investigation of the usability of hepatoma cell lines HepG2 and Huh7 as models for the metabolic representation of resectable hepatocellular carcinoma. Cancers (Basel). 2022. https://doi.org/10.3390/cancers14174227.

Article  PubMed  Google Scholar 

Chou T-C. Frequently asked questions in drug combinations and the mass-action law-based answers. Synergy. 2014;1:3–21. https://doi.org/10.1016/j.synres.2014.07.003.

Article  Google Scholar 

Chou T-C. The combination index (CI < 1) as the definition of synergism and of synergy claims. Synergy. 2018;7:49–50. https://doi.org/10.1016/j.synres.2018.04.001.

Article  Google Scholar 

Muller P, Hrstka R, Coomber D, Lane DP, Vojtesek B. Chaperone-dependent stabilization and degradation of p53 mutants. Oncogene. 2008;27:3371–83. https://doi.org/10.1038/sj.onc.1211010.

Article  CAS  PubMed  Google Scholar 

Trepel J, Mollapour M, Giaccone G, Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer. 2010;10:537–49. https://doi.org/10.1038/nrc2887.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Augello G, Emma MR, Cusimano A, Azzolina A, Mongiovì S, Puleio R, et al. Targeting HSP90 with the small molecule inhibitor AUY922 (luminespib) as a treatment strategy against hepatocellular carcinoma. Int J Cancer. 2019;144:2613–24. https://doi.org/10.1002/ijc.31963.

Article  CAS  PubMed  Google Scholar 

Wang C, Zhang Y, Guo K, Wang N, Jin H, Liu Y, et al. Heat shock proteins in hepatocellular carcinoma: molecular mechanism and therapeutic potential. Int J Cancer. 2016;138:1824–34. https://doi.org/10.1002/ijc.29723.

Article  CAS  PubMed  Google Scholar 

Ramalingam M, Jang S, Jeong HS. Therapeutic effects of conditioned medium of neural differentiated human bone marrow-derived stem cells on rotenone-induced alpha-synuclein aggregation and apoptosis. Stem Cells Int. 2021;2021:6658271. https://doi.org/10.1155/2021/6658271.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Anwanwan D, Singh SK, Singh S, Saikam V, Singh R. Challenges in liver cancer and possible treatment approaches. Biochim Biophys Acta Rev Cancer. 2020;1873:188314. https://doi.org/10.1016/j.bbcan.2019.188314.

Article  CAS  PubMed  Google Scholar 

Daunys S, Matulis D, Petrikaitė V. Synergistic activity of Hsp90 inhibitors and anticancer agents in pancreatic cancer cell cultures. Sci Rep. 2019;9:16177. https://doi.org/10.1038/s41598-019-52652-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gupta B, Pathak S, Poudel BK, Regmi S, Ruttala HB, Gautam M, et al. Folate receptor-targeted hybrid lipid-core nanocapsules for sequential delivery of doxorubicin and tanespimycin. Colloids Surf B. 2017;155:83–92. https://doi.org/10.1016/j.colsurfb.2017.04.010.

Article  CAS  Google Scholar 

Lai CH, Park KS, Lee DH, Alberobello AT, Raffeld M, Pierobon M, et al. HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer. Oncogene. 2014;33:4867–76. https://doi.org/10.1038/onc.2013.439.

Article  CAS  PubMed  Google Scholar 

Akce M, Alese OB, Shaib WL, Wu C, Lesinski GB, El-Rayes BF. Phase Ib trial of pembrolizumab and XL888 in patients with advanced gastrointestinal malignancies: results of the dose-escalation phase. J Clin Oncol. 2020;38:830–830. https://doi.org/10.1200/JCO.2020.38.4_suppl.830.

Article